Document is current
Any future updates will be listed below
-
Authors
Mäkelä, Rami
Arjonen, Antti
Härmä, Ville
Rintanen, Nina
Paasonen, Lauri
Paprotka, Tobias
Rönsch, Kerstin
Kuopio, Teijo
Kononen, Juha
Rantala, Juha K. http://orcid.org/0000-0002-4999-5585
-
Funding
Funding for this research was provided by:
AstraZeneca (18122013)
- License Information
-
More Information
Article History
Received: 6 May 2019
Accepted: 19 June 2020
First Online: 23 June 2020
Ethics approval and consent to participate
: The study was approved by the Institutional Review Board of the Central Finland Health Care District. The use and investigation of the patient derived cells was conducted in accordance with approval by the local Ethics Committee of the Central Finland Health Care District (KSSHP 3 U/2015). All experiments were undertaken with the understanding and written informed consent of the patient. The study methodologies conformed to the standards set by the Declaration of Helsinki.
: Not applicable.
: The authors of this manuscript declare that they have no competing interests. Juha K. Rantala is the founder of Misvik Biology Oy.
